Current knowledge on Hepatitis Delta Virus replication

Lucifora, Julie; Delphin, Marion

doi:10.1016/j.antiviral.2020.104812

Cited by 36 publications

(43 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to other RNA viruses that encode RNA-dependent RNA-polymerases (RdRP) for replication and mRNA synthesis, HDV recruits and reprogrammes the cellular Pol II to achieve these goals. 2 Accordingly, an important viral drug target (the RdRP) is lacking. Nevertheless, crucial steps in the viral life cycle like the ribozyme-mediated self-cleavage of genomic and antigenomic RNA oligomers or the HDAg-dependent regulation of RNA replication and mRNA synthesis are attractive viral structures suitable for drug targeting.…”

Section: Interfering With Viral Replication Viral Targetsmentioning

confidence: 99%

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

Urban

Neumann‐Haefelin

Lampertico

2021

Gut

144

171

View full text Add to dashboard Cite

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5–10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific therapies targeting viral or host factors. Pegylated interferon-α has been used for treating HDV patients for the last 30 years with only limited sustained responses. Here we describe novel treatment options with regard to their mode of action and their clinical effectiveness. Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex). One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.

show abstract

Section: Interfering With Viral Replication Viral Targetsmentioning

confidence: 99%

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

Urban

Neumann‐Haefelin

Lampertico

2021

Gut

144

171

View full text Add to dashboard Cite

show abstract

“…For a more detailed description of the viral life cycle see referred reviews. 31,36,37 HDV persistence, dissemination and spread Since HDV replicates via episomal RNAs, persistence probably requires continuous de novo RNA synthesis (although we presently cannot exclude the presence of inactive HDV RNAs serving as reservoir for reactivation).…”

Section: Hdv Replication Cyclementioning

confidence: 99%

New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies

Zhang

Urban

2021

Journal of Hepatology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…HBV presence is mandatory for HDV replication, since HBsAg is required for HDV cell entry by NTCP, virion assembly, and export; however, its RNA replication is autonomous. HDV is maintained as episomes in the nucleus of the infected hepatocytes and transcribes the viral RNAs on behalf of the host cell machinery[ 156 ].…”

Section: Hcvmentioning

confidence: 99%

Viral hepatitis update: Progress and perspectives

Pisano¹,

Giadans²,

Flichman³

et al. 2021

WJG

View full text Add to dashboard Cite

Viral hepatitis, secondary to infection with hepatitis A, B, C, D, and E viruses, are a major public health problem and an important cause of morbidity and mortality. Despite the huge medical advances achieved in recent years, there are still points of conflict concerning the pathogenesis, immune response, development of new and more effective vaccines, therapies, and treatment. This review focuses on the most important research topics that deal with issues that are currently being solved, those that remain to be solved, and future research directions. For hepatitis A virus we will address epidemiology, molecular surveillance, new susceptible populations as well as environmental and food detections. In the case of hepatitis B virus, we will discuss host factors related to disease, diagnosis, therapy, and vaccine improvement. On hepatitis C virus, we will focus on pathogenesis, immune response, direct action antivirals treatment in the context of solid organ transplantation, issues related to hepatocellular carcinoma development, direct action antivirals resistance due to selection of resistance-associated variants, and vaccination. Regarding hepatitis D virus, we describe diagnostic methodology, pathogenesis, and therapy. Finally, for hepatitis E virus, we will address epidemiology (including new emerging species), diagnosis, clinical aspects, treatment, the development of a vaccine, and environmental surveillance.

show abstract

Current knowledge on Hepatitis Delta Virus replication

Cited by 36 publications

References 137 publications

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease

New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies

Viral hepatitis update: Progress and perspectives

Contact Info

Product

Resources

About